Dodge & Cox Neurocrine Biosciences Inc Call Options Transaction History
Dodge & Cox
- $164 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
653Shares Held
96.4MCall Options Held
800KPut Options Held
565K-
Black Rock Inc. New York, NY14.2MShares$1.82 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.28 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.86MShares$624 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$343 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.5MShares$321 Million0.44% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.3B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...